Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced plans to present first-in-human data for MK-2214 and MK-1167 at Clinical Trials on Alzheimer’s Disease (CTAD) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback